Na_v1.7 and other voltage-gated sodium channels as drug targets for pain relief

References

• Minett MS, Falk S, Santana-Varela S, et al. Pain without nociceptors? Nav1.7-independent pain mechanisms. Cell Rep. 2014;6(2):301–12.
   PubMed Web of Science ®Google Scholar
• Dobney GH, Belam OH. The scope of nerve root block in physical medicine. Proc R Soc Med. 1963;56:444–6.
   PubMedGoogle Scholar
• Bonica JJ. Management of pain with regional analgesia. Postgrad Med J. 1984;60(710):897–904.
   PubMed Web of Science ®Google Scholar
• Fritz J, Chhabra A, Wang KC, et al. Magnetic resonance neurography-guided nerve blocks for the diagnosis and treatment of chronic pelvic pain syndrome. Neuroimaging Clin N Am. 2014;24(1):211–234.
   PubMed Web of Science ®Google Scholar
• Eijkelkamp N, Linley JE, Baker MD, et al. Neurological perspectives on voltage-gated sodium channels. Brain. 2012;135(Pt 9):2585–2612.
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD, Black JA, Waxman SG. Nav1.9: a sodium channel linked to human pain. Nat Rev Neurosci. 2015;16(9):511–519.
   PubMed Web of Science ®Google Scholar
• Leipold E, Hanson-Kahn A, Frick M, et al. Cold-aggravated pain in humans caused by a hyperactive Nav1.9 channel mutant. Nat Commun. 2015;6:10049.
   PubMed Web of Science ®Google Scholar
• Wood JN, Baker M. Voltage-gated sodium channels. Curr Opin Pharmacol. 2001;1(1):17–21.
   PubMedGoogle Scholar
• Ogata N, Ohishi Y. Molecular diversity of structure and function of the voltage-gated Na+ channels. Jpn J Pharmacol. 2002;88(4):365–377.
   PubMedGoogle Scholar
• Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 4th edition. Br J Pharmacol. 2009;158:S1–S239.
   Google Scholar
• Lees G, Shipton E. Voltage-gated sodium channels in nociception and their potential as targets for new drugs in treatment of chronic neuropathic pain. Curr Anaesthesia Crit Care. 2009;20(5–6):204–208.
   Google Scholar
• Vickery RG, Amagasu SM, Chang R, et al. Comparison of the pharmacological properties of rat Na(V)1.8 with rat Na(V)1.2a and human Na(V)1.5 voltage-gated sodium channel subtypes using a membrane potential sensitive dye and FLIPR. Recept Channels. 2004;10(1):11–23.
   PubMedGoogle Scholar
• Nassar MA, Stirling LC, Forlani G, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. 2004;101(34):12706–12711.
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Zhao J, Asante CO, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science. 2008;321(5889):702–705.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Y, Li S, et al.. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41(3):171–174.
   PubMed Web of Science ®Google Scholar
• Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004;24(38):8232–8236.
   PubMed Web of Science ®Google Scholar
• Waxman SG. Painful Na-channelopathies: an expanding universe. Trends Mol Med. 2013;19(7):406–409.
   PubMed Web of Science ®Google Scholar
• Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52(5):767–774.
   PubMed Web of Science ®Google Scholar
• Estacion M, Harty TP, Choi J-S, et al. A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Ann Neurol. 2009;66(6):862–866.
   PubMed Web of Science ®Google Scholar
• Theile JW, Jarecki BW, Piekarz AD, et al. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. J Physiol. 2011;589(Pt 3):597–608.
   PubMed Web of Science ®Google Scholar
• Eberhardt M, Nakajima J, KLinger AB, et al. Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation. J Biol Chem. 2014;289(4):1971–1980.
   PubMed Web of Science ®Google Scholar
• Emery EC, Habib AM, Cox JJ, et al. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations. J Neurosci. 2015;35(20):7674–7681.
   PubMed Web of Science ®Google Scholar
• Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121):894–8.
   PubMed Web of Science ®Google Scholar
• Sun S, Cohen CJ, Dehnhardt CM. Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010. Pharm Pat Anal. 2014;3(5):509–521.
   PubMedGoogle Scholar
• Convergence Pharmaceuticals, C., UK. Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy. [ updated 2014 Sep 23; [cited Jan, 2016] Available from: http://www.convergencepharma.com/userfiles/file/140923_LSR_FINAL.pdf.
   Google Scholar
• Convergence Pharmaceuticals, C., UK. CNV1014802. 2016 [cited 2016 Jan] Available from: http://www.convergencepharma.com/index.asp?page_id=14.
   Google Scholar
• Convergence Pharmaceuticals, C., UK. Convergence pharmaceuticals receives orphan-drug designation for Nav1.7 blocking pain drug CNV1014802. [ updated Jul 30 2013; [cited 2016 Jan] Available from: http://www.convergencepharma.com/userfiles/file/Orphan%20Drug%20Designation_Final.pdf.
   Google Scholar
• Convergence Pharmaceuticals, C., UK. The Pipeline. 2016 [cited 2016 Jan] Available from: http://www.convergencepharma.com/?page_id=16.
   Google Scholar
• Convergence Pharmaceuticals, C., UK. A Phase I ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidates. [ updated 2013 Oct 29; cited 2016 Jan] Available from: http://www.convergencepharma.com/userfiles/file/131029%20Convergence_%20436%20press%20release%20final%20complete.pdf.
   Google Scholar
• Convergence Pharmaceuticals, C., UK. Convergence presentations and posters (preclinical properties of CNV3000223, a new Nav1.7 selective blocker with broad anti-hyperalgesic efficacy). 8th Congress of the European Federation of IASP Chapters (EFIC) - Pain in Europe V; 2013 Oct 9–12; Florence, Italy. 2016; http://www.convergencepharma.com/index.asp?page_id=29 [cited 2016 Jan].
   Google Scholar
• Xenon Pharmaceuticals Inc., V., Canada. Xenon’s XEN402 ointment significantly relieves pain in patients with post herpetic neuralgia. [ updated 2011 May 2;cited 2016 Jan]. Available from: http://www.xenon-pharma.com/2011/05/xenon%E2%80%99s-xen402-ointment-significantly-relieves-pain-in-patients-with-post-herpetic-neuralgia/.
   Google Scholar
• Xenon Pharmaceuticals Inc., V., Canada. TV-45070 for the treatment of pain. 2015 [cited 2016 Jan] Available from: http://www.xenon-pharma.com/product-candidates/pain/pain-teva/.
   Google Scholar
• Genentech. Pipeline. 2016 [cited 2016 Jan] Available from: http://www.gene.com/medical-professionals/pipeline.
   Google Scholar
• AdisInsight (Adis International Ltd, p.o.S.S.B.M. Drug Profile (GDC-0310). 2016 [cited 2016 Jan] Available from: http://adisinsight.springer.com/drugs/800043573.
   Google Scholar
• Dainippon Sumitomo Pharma Co., L. Supplementary financial data for the third quarter of the year ending March 31, 2013. [ updated 2013 Jan 31; cited 2016 January]. Available from: http://www.ds-pharma.com/pdf_view.php?id=278.
   Google Scholar
• Gursahani H, Kim G, Gogas K, et al. NKTR-171: A novel sodium channel blocker for neuropathic pain with reduced CNS side effects. Abstract # 8106/ Poster #JJ11: Presented at the Society for Neuroscience 42nd Annual Meeting: Neuroscience 2012; 2012 Oct 13–17; New Orleans, LA. [cited 2012 Oct 13–17].
   Google Scholar
• Chromocell Corporation, N.B.T., USA. Analgesia program. 2016 [cited 2016 January]. Available from: http://www.chromocell.com/index2.php?sprache=eng&nav=therapeutics&unternav=therapeutics_programs&intern=therapeutics_programs.
   Google Scholar
• De Lera Ruiz M, Kraus RL. Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. J Med Chem. 2015;58(18):7093–7118.
   PubMed Web of Science ®Google Scholar
• Wheeler DW, Lee MC, Harrison EK, et al. Case report: neuropathic pain in a patient with congenital insensitivity to pain [version 2; referees: 2 approved]. F1000Research. 2015;3(135).
   Google Scholar
• Lee JH, Park. CK, Chen G, et al. A monoclonal antibody that targets a Nav1.7 channel voltage sensor for pain and itch relief. Cell. 2014;157(6):1393–1404.
   PubMed Web of Science ®Google Scholar
• Dehen H, Willer JC, Prier S, et al. Congenital insensitivity to pain and the “morphine-like” analgesic system. Pain. 1978;5(4):351–358.
   PubMed Web of Science ®Google Scholar
• Minett MS, Pereira V, Sikandar S, et al. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7. Nat Commun. 2015;6:8967.
   PubMed Web of Science ®Google Scholar
• Minett MS, Eijkelkamp N, Wood JN. Significant determinants of mouse pain behaviour. PLoS One. 2014;9(8):e104458.
   Google Scholar
• Minett MS, Nassar MA, Clark AK, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun. 2012;3:791.
   PubMed Web of Science ®Google Scholar
• Poras H, Bonnard E, Dangé E, et al. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment. J Med Chem. 2014;57(13):5748–5763.
   PubMed Web of Science ®Google Scholar
• Miyakawa H, Woo SK, Dahl SC, et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci U S A. 1999;96(5):2538–2542.
   PubMed Web of Science ®Google Scholar
• Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999;2(6):541–8.
   PubMed Web of Science ®Google Scholar
• Nassar MA, Levato A, Stirling LC, et al. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Molecular Pain. 2005;1:24.
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Leffler A, Babes A, et al. Sensory neuron sodium channel Nav1. 8 is essential for pain at low temperatures. Nature. 2007;447(7146):856–859.
   Web of Science ®Google Scholar
• Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med. 2012;18(6):926–933.
   PubMed Web of Science ®Google Scholar
• Faber CG, Lauria G, Merkies IS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A. 2012;109(47):19444–19449.
   PubMed Web of Science ®Google Scholar
• Huang J, Yang Y, Zhao P, et al. Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci. 2013;33(35):14087–14097.
   PubMed Web of Science ®Google Scholar
• Han C, Vasylyev D, Macala LJ, et al. The G1662S Nav1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry. 2014;85(5):499–505.
   PubMed Web of Science ®Google Scholar
• Chambers JC, Zhao J, Terracciano CM, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42(2):149–152.
   PubMed Web of Science ®Google Scholar
• Bagal SK, Bungay PJ, Dentom SM, et al. Discovery and optimization of selective Nav1.8 modulator series that demonstrate efficacy in preclinical models of pain. ACS Med Chem Lett. 2015;6(6):650–654.
   PubMed Web of Science ®Google Scholar
• Verkerk AO, Remme CA, Schumacher CA, et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ Res. 2012;111(3):333–343.
   PubMed Web of Science ®Google Scholar
• Holm H, Gudbjartsson DF, Arnar DO, et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat Genet. 2010;42(2):117–122.
   PubMed Web of Science ®Google Scholar
• Sotoodehnia N, Isaacs A, De Bakker PI, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet. 2010;42(12):1068–1076.
   PubMed Web of Science ®Google Scholar
• Pfeufer A, Van Noord C, Marciante KD, et al. Genome-wide association study of PR interval. Nat Genet. 2010;42(2):153–159.
   PubMed Web of Science ®Google Scholar
• Yang T, Atack TC, Stroud DM, et al. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res. 2012;111(3):322–332.
   PubMed Web of Science ®Google Scholar
• Lolignier S, Amsalem M, Maingret F, et al. Nav1.9 channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation. PLoS One. 2011;6(8):e23083.
   Google Scholar
• Leo S, D’Hooge R, Meert T. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav Brain Res. 2010;208(1):149–157.
   PubMed Web of Science ®Google Scholar
• Priest BT, Murphy BA, Lindia JA, et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci U S A. 2005;102(26):9382–9387.
   PubMed Web of Science ®Google Scholar
• Amaya F, Wang H, Costigan M, et al. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci. 2006;26(50):12852–12860.
   PubMed Web of Science ®Google Scholar
• Hillsley K, Lim JH, Stanisz A, et al. Dissecting the role of sodium currents in visceral sensory neurons in a model of chronic hyperexcitability using Nav1.8 and Nav1.9 null mice. J Physiol. 2006;576(Pt 1):257–267.
   PubMed Web of Science ®Google Scholar
• Sleeper AA, Cummins TR, Dib-Hajj SD, et al. Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. J Neurosci. 2000;20(19):7279–7289.
   PubMed Web of Science ®Google Scholar
• Luiz AP, Kopach O, Santana-Varela S, et al. The role of Na1.9 channel in the development of neuropathic orofacial pain associated with trigeminal neuralgia. Mol Pain. 2015;11(1):72.
   PubMed Web of Science ®Google Scholar
• Huang J, Han C, Estacion M, et al. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain. 2014;137(Pt 6):1627–1642.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Wen J, Yang W, et al. Gain-of-function mutations in SCN11A cause familial episodic pain. Am J Hum Genet. 2013;93(5):957–966.
   PubMed Web of Science ®Google Scholar
• Han C, Yang Y, De Greef BT, et al. The domain II S4-S5 linker in Nav1.9: a missense mutation enhances activation, impairs fast inactivation, and produces human painful neuropathy. Neuromolecular Med. 2015;17(2):158–169.
   PubMed Web of Science ®Google Scholar
• Leipold E, Leibmann L, Korenke GC, et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet. 2013;45(11):1399–1404.
   PubMed Web of Science ®Google Scholar
• Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin). 2012;6(5):352–361.
   PubMed Web of Science ®Google Scholar
• Jansson KH, Castillo DG, Morris JW, et al. Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach. PLoS One. 2014;9(6):e98408.
   Google Scholar
• Brisson L, Gillet L, Calaghan S, et al. Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene. 2011;30(17):2070–2076.
   PubMed Web of Science ®Google Scholar
• Brisson L, Reshkin SJ, Gore J, et al. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol. 2012;91(11–12):847–860.
   PubMed Web of Science ®Google Scholar
• Morinville A, Fundin B, Meury L, et al. Distribution of the voltage-gated sodium channel Na(v)1.7 in the rat: expression in the autonomic and endocrine systems. J Comp Neurol. 2007;504(6):680–689.
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD, Yang Y, Black JA, et al. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14(1):49–62.
   PubMed Web of Science ®Google Scholar
• Black JA, Hoeijmakers JG, Faber CG, et al. Nav1.7: stress-induced changes in immunoreactivity within magnocellular neurosecretory neurons of the supraoptic nucleus. Mol Pain. 2013;9:39.
   PubMed Web of Science ®Google Scholar
• Weiss J, Pyrski M, Jacobi E, et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature. 2011;472(7342):186–190.
   PubMed Web of Science ®Google Scholar
• Salat K, Kowalczyk P, Gryzio B, et al. New investigational drugs for the treatment of neuropathic pain. Expert Opin Investig Drugs. 2014;23(8):1093–1104.
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov (A service of the U.S. National Institutes of Health). Safety & efficacy study of subcutaneous tetrodotoxin for moderate to severe inadequately controlled cancer-related pain (TEC-006). [ updated 2016 Jan 04; cited 2016 Jan]. Available from: https://www.clinicaltrials.gov/ct2/show/nct00725114.
   Google Scholar
• Le Guiner C, Stieger K, Toromanoff A, et al. Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates. PLoS One. 2014;9(9).
   Web of Science ®Google Scholar
• Katzel D, Nicholson E, Schorge S, et al. Chemical-genetic attenuation of focal neocortical seizures. Nat Commun. 2014;5:3847.
   PubMed Web of Science ®Google Scholar
• Koenig J, Werdehausen R, Linley JE, et al. Regulation of Nav1.7: a conserved SCN9A natural antisense transcript expressed in dorsal root ganglia. PLoS One. 2015;10(6):e0128830.
   Google Scholar